A Drug Interaction Study of KW-6356 and Clarithromycin or Rifampicin
NCT ID: NCT04070495
Last Updated: 2019-11-29
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE1
20 participants
INTERVENTIONAL
2019-08-27
2019-11-19
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Clarithromycin
KW-6356
A single oral dose will be administered at Day 1 and 15
Clarithromycin
400mg, oral tablet (2 x 200mg), twice daily (BID), Day 8-28
Rifampicin
KW-6356
A single oral dose will be administered at Day 1 and 15
Rifampicin
600mg, oral tablet (4 x 150mg), once daily (QD), Day 8-21
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
KW-6356
A single oral dose will be administered at Day 1 and 15
Clarithromycin
400mg, oral tablet (2 x 200mg), twice daily (BID), Day 8-28
Rifampicin
600mg, oral tablet (4 x 150mg), once daily (QD), Day 8-21
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Japanese men aged 20 to 44 years at the time of informed consent
3. Subjects with BMI ≥18.5 and \<25.0 at screening
4. Subjects with screening results of; resting pulse rate: 40 to 100 bpm, systolic blood pressure: 90 to 139 mmHg, diastolic blood pressure: 40 to 89 mmHg
Exclusion Criteria
2. Subjects having drug allergy or its history
3. Subjects having psychiatric disease or its history
4. Positive results for any of the following infection-related items examined at screening: hepatitis B surface (HBs) antigen, HBs antibody, hepatitis B core (HBc) antibody, hepatitis C virus (HCV) antibody, human immunodeficiency virus (HIV) antigen/antibody, human T-lymphotropic virus (HTLV)-1 antibody, rapid plasma reagin (PRP) test, or Treponema pallidum (TP) antibody.
5. Subjects with clinically significant abnormality detected on 12-lead electrocardiogram (ECG) recorded prior to the first administration of investigational product.
6. Subjects categorized as patients listed in the warnings or contraindications section of the package insert of the perpetrator drug.
7. Subjects having used any drug (including over-the-counter \[OTC\] drugs, topical agents, vitamin preparations, health supplements, and Chinese herbal medicines) within 2 weeks prior to the first administration of investigational product.
8. Subjects having consumed grapefruit (including any food or beverage containing grapefruit) or any food or beverage containing St John's wort within 1 week prior to the first administration of investigational product.
9. Subjects having smoked or used smoking cessation agents (including chewing or eating of nicotine-containing products and application of nicotine patches) within 4 weeks prior to the first administration of investigational product.
10. Subjects having received inpatient treatment or surgery within 12 weeks prior to the first administration of investigational product.
11. Subjects having participated in a clinical study of a pharmaceutical product or a medical device or any equivalent study and used the investigational product or the unapproved medical device within 4 months prior to the first administration of investigational product.
12. Subjects having undergone ≥400 mL of blood collection within 12 weeks prior to the first administration of investigational product or ≥200 mL of blood collection within 4 weeks prior to the first administration of investigational product (for blood donation or clinical trial, etc.) or pheresis donation (plateletpheresis or plasmapheresis donation) within 2 weeks prior to the first administration of investigational product.
13. Subjects having issued no consent to adoption of any appropriate contraceptive method during the period from day of admission to 12 weeks after the final administration of the perpetrator drug. The appropriate contraceptive method is defined as sexual abstinence or use of 2 of the following contraceptive devices: condom, oral contraceptives, intrauterine device, and pessary.
14. Subjects having received KW-6356 before.
15. Other subjects unsuitable for participating in the study in the opinion of the investigator or subinvestigator.
20 Years
44 Years
MALE
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Kyowa Kirin Co., Ltd.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Medical Co. LTA Sumida Hospital
Sumida-ku, Tokyo, Japan
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
6356-008
Identifier Type: -
Identifier Source: org_study_id